Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag plus immunosuppressive therapy in treatment-naive severe aplastic anemia
ChiCTR2100054957Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of eltrombopag in aplastic anemia (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Hematologic response rate. Started Dec 2021; status: recruiting.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2100054957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054957.